Results 111 to 120 of about 54,905 (262)
Serology of primary biliary cirrhosis [PDF]
Peter A. Berg, Harold Baum
openalex +1 more source
A case of gastric cardia telangiectasias and primary biliary cirrhosis with hemorrhage. [PDF]
Guo J.
europepmc +1 more source
Interventional oncology in children: Where are we now?
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel +1 more
wiley +1 more source
Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review. [PDF]
Mago S, Wu GY.
europepmc +1 more source
Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes +2 more
wiley +1 more source
Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis
Minoru Nakamura
openalex +2 more sources
Primary Biliary Cirrhosis Scenario of Libyan Patients in Tripoli University Hospital
S Omar +3 more
openalex +2 more sources
This study evaluated the performance of the PAGE‐B score in HCC risk among CHB patients with metabolic dysfunction or MASLD. The PAGE‐B score effectively stratified HCC risk in both MASLD and non‐MASLD patients, especially in those without cirrhosis, where low scores were linked to negligible 5‐year HCC risk. ABSTRACT Introduction Metabolic dysfunction
Lesley A. Patmore +22 more
wiley +1 more source
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas +18 more
wiley +1 more source

